NEXICLON XR Drug Patent Profile
✉ Email this page to a colleague
When do Nexiclon Xr patents expire, and what generic alternatives are available?
Nexiclon Xr is a drug marketed by Rosemont and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-one patent family members in fourteen countries.
The generic ingredient in NEXICLON XR is clonidine. There are twenty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clonidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nexiclon Xr
A generic version of NEXICLON XR was approved as clonidine by MYLAN TECHNOLOGIES on July 16th, 2010.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NEXICLON XR?
- What are the global sales for NEXICLON XR?
- What is Average Wholesale Price for NEXICLON XR?
Summary for NEXICLON XR
| International Patents: | 21 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 69 |
| Clinical Trials: | 4 |
| Patent Applications: | 3,412 |
| What excipients (inactive ingredients) are in NEXICLON XR? | NEXICLON XR excipients list |
| DailyMed Link: | NEXICLON XR at DailyMed |
Recent Clinical Trials for NEXICLON XR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Louisville | Phase 4 |
| Arthroplasty Foundation, Inc. | Phase 4 |
| Children's Hospital of Pittsburgh | N/A |
Pharmacology for NEXICLON XR
| Drug Class | Central alpha-2 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha2-Agonists |
US Patents and Regulatory Information for NEXICLON XR
NEXICLON XR is protected by two US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rosemont | NEXICLON XR | clonidine | TABLET, EXTENDED RELEASE;ORAL | 022500-001 | Dec 3, 2009 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Rosemont | NEXICLON XR | clonidine | TABLET, EXTENDED RELEASE;ORAL | 022500-002 | Dec 3, 2009 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Rosemont | NEXICLON XR | clonidine | TABLET, EXTENDED RELEASE;ORAL | 022500-001 | Dec 3, 2009 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NEXICLON XR
See the table below for patents covering NEXICLON XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | E536867 | ⤷ Start Trial | |
| Australia | 2007227569 | Modified release formulations containing drug-ion exchange resin complexes | ⤷ Start Trial |
| Brazil | PI0709606 | suspensão líquida administrável oralmente com características de liberação modificada | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch